Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease

Pharmacology and Therapeutics

Volumn 139, Issue 1, 2013, Pages 41-50

  Adwan, Lina ^a   Zawia, Nasser H ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Alzheimer's disease; DNA methylation; Epigenetics; Histone modification; Memory; Therapy

Indexed keywords

4 PHENYLBUTYRIC ACID; ACETYLCYSTEINE; AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; BETAINE; BUTYRIC ACID; CILOSTAZOL; CREBINOSTAT; CURCUMIN; DNA; DONEPEZIL; E1A ASSOCIATED P300 PROTEIN; ERYTHROMYCIN; EVP 0334; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE; PAROXETINE; PLACEBO; RESVERATROL; ROMIDEPSIN; S ADENOSYLMETHIONINE; SIRTUIN; SRT 2104; SRT 2379; TOLFENAMIC ACID; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VALPROIC ACID; VORINOSTAT;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; BIPOLAR DISORDER; BRAIN; COGNITIVE DEFECT; CUTANEOUS T CELL LYMPHOMA; DEGENERATIVE DISEASE; DEMENTIA; DNA METHYLATION; EPIGENETICS; EPILEPSY; GENE EXPRESSION; HISTONE MODIFICATION; HOMOCYSTINURIA; HUMAN; LEARNING; MEMORY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; DNA METHYLATION; EPIGENOMICS; HISTONES; HUMANS;

EID: 84877927154     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.03.010     Document Type: Review

References (210)

1. M. Abdelrahim, C.H. Baker, J.L. Abbruzzese, and S. Safe Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation J Natl Cancer Inst 98 2006 855 868
2. T. Abel, and R.S. Zukin Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders Curr Opin Pharmacol 8 2008 57 64
3. L.I. Adwan, R. Basha, M. Abdelrahim, G.M. Subaiea, and N.H. Zawia Tolfenamic acid interrupts the de novo synthesis of the beta-amyloid precursor protein and lowers amyloid beta via a transcriptional pathway Curr Alzheimer Res 8 2011 385 392
4. H. Alashwal, R. Dosunmu, and N.H. Zawia Integration of genome-wide expression and methylation data: Relevance to aging and Alzheimer's disease Neurotoxicology 33 2012 1450 1453
5. D. Albani, L. Polito, and G. Forloni Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: Experimental and genetic evidence J Alzheimers Dis 19 2010 11 26
6. A.D. Alonso, I. Grundke-Iqbal, H.S. Barra, and K. Iqbal Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau Proc Natl Acad Sci U S A 94 1997 298 303
7. Alzheimer's Association 2012 Alzheimer's disease facts and figures Alzheimers Dement 8 2012 131 168
8. Alzheimer's Association 2013 Alzheimer's disease facts and figures Alzheimers Dement 9 2013 208 245
9. R.E. Amir, I.B. Van den Veyver, M. Wan, C.Q. Tran, U. Francke, and H.Y. Zoghbi Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 Nat Genet 23 1999 185 188
10. C.H. Arrowsmith, C. Bountra, P.V. Fish, K. Lee, and M. Schapira Epigenetic protein families: A new frontier for drug discovery Nat Rev Drug Discov 11 2012 384 400
11. K.M. Bakulski, D.C. Dolinoy, M.A. Sartor, H.L. Paulson, J.R. Konen, and A.P. Lieberman Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex J Alzheimers Dis 29 2012 571 588
12. K. Balasubramanyam, R.A. Varier, M. Altaf, V. Swaminathan, N.B. Siddappa, and U. Ranga Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription J Biol Chem 279 2004 51163 51171
13. B. Barneda-Zahonero, and M. Parra Histone deacetylases and cancer Mol Oncol 6 2012 579 589
14. D.E. Barnes, and K. Yaffe The projected effect of risk factor reduction on Alzheimer's disease prevalence Lancet Neurol 10 2011 819 828
15. M. Barrachina, and I. Ferrer DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain J Neuropathol Exp Neurol 68 2009 880 891
16. A.N. Begum, M.R. Jones, G.P. Lim, T. Morihara, P. Kim, and D.D. Heath Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease J Pharmacol Exp Ther 326 2008 196 208
17. S.W. Bihaqi, A. Bahmani, G.M. Subaiea, and N.H. Zawia Infantile exposure to lead (Pb) and late age cognitive decline: relevance to AD Alzheimers Dement 2013 (in press)
18. S.W. Bihaqi, H. Huang, J. Wu, and N.H. Zawia Infant exposure to lead (Pb) and epigenetic modifications in the aging primate brain: Implications for Alzheimer's disease J Alzheimers Dis 27 2011 819 833
19. S.W. Bihaqi, and N.H. Zawia Alzheimer's disease biomarkers and epigenetic intermediates following exposure to Pb in vitro Curr Alzheimer Res 9 2012 555 562
20. A. Bird CpG-rich islands and the function of DNA methylation Nature 321 1986 209 213
21. A. Bird Perceptions of epigenetics Nature 447 2007 396 398
22. H. Bito, K. Deisseroth, and R.W. Tsien CREB phosphorylation and dephosphorylation: A Ca(2+)- and stimulus duration-dependent switch for hippocampal gene expression Cell 87 1996 1203 1214
23. T. Bottiglieri, P. Godfrey, T. Flynn, M.W. Carney, B.K. Toone, and E.H. Reynolds Cerebrospinal fluid S-adenosylmethionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosylmethionine J Neurol Neurosurg Psychiatry 53 1990 1096 1098
24. T. Bottiglieri, K. Hyland, and E.H. Reynolds The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders Drugs 48 1994 137 152
25. A. Caccamo, M.A. Maldonado, A.F. Bokov, S. Majumder, and S. Oddo CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease Proc Natl Acad Sci U S A 107 2010 22687 22692
26. F. Caraci, G.M. Leggio, F. Drago, and S. Salomone Epigenetic drugs for Alzheimer's Disease: Hopes and challenges Br J Clin Pharmacol 75 2012 1154 1155
27. L.H. Chadwick The NIH roadmap epigenomics program data resource Epigenomics 4 2012 317 324
28. M. Chahrour, S.Y. Jung, C. Shaw, X. Zhou, S.T. Wong, and J. Qin MeCP2, a key contributor to neurological disease, activates and represses transcription Science 320 2008 1224 1229
29. T. Chen, Y. Ueda, J.E. Dodge, Z. Wang, and E. Li Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b Mol Cell Biol 23 2003 5594 5605
30. L. Chouliaras, D.L. van den Hove, G. Kenis, J. Dela Cruz, M.A. Lemmens, and J. van Os Caloric restriction attenuates age-related changes of DNA methyltransferase 3a in mouse hippocampus Brain Behav Immun 25 2011 616 623
31. L. Chouliaras, D.L. van den Hove, G. Kenis, S. Keitel, P.R. Hof, and J. van Os Age-related increase in levels of 5-hydroxymethylcytosine in mouse hippocampus is prevented by caloric restriction Curr Alzheimer Res 9 2012 536 544
32. L. Chouliaras, D.L. van den Hove, G. Kenis, S. Keitel, P.R. Hof, and J. van Os Prevention of age-related changes in hippocampal levels of 5-methylcytidine by caloric restriction Neurobiol Aging 33 2012 1672 1681
33. W.B. Chwang, K.J. O'Riordan, J.M. Levenson, and J.D. Sweatt ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning Learn Mem 13 2006 322 328
34. M. Citron, D.B. Teplow, and D.J. Selkoe Generation of amyloid beta protein from its precursor is sequence specific Neuron 14 1995 661 670
35. ClinicalTrials.gov 18-Month Study of Curcumin: ClinicalTials.gov identifier NCT01383161 2012
36. ClinicalTrials.gov Safety Study of Nicotinamide to Treat Alzheimer's Disease: ClinicalTrials.gov identifier NCT00580931 2012
37. ClinicalTrials.gov Cilostazol Augmentation Study in Dementia: ClinicalTrials.gov identifier NCT01409564 2011
38. ClinicalTrials.gov Resveratrol for Alzheimer's Disease: ClinicalTrials.gov identifier NCT01504854 2013
39. J.P. Cogswell, J. Ward, I.A. Taylor, M. Waters, Y. Shi, and B. Cannon Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways J Alzheimers Dis 14 2008 27 41
40. T.J. Cohen, J.L. Guo, D.E. Hurtado, L.K. Kwong, I.P. Mills, and J.Q. Trojanowski The acetylation of tau inhibits its function and promotes pathological tau aggregation Nat Commun 2 2011 252
41. F.F. Costa Non-coding RNAs, epigenetics and complexity Gene 410 2008 9 17
42. H.E. Covington III, I. Maze, Q.C. LaPlant, V.F. Vialou, Y.N. Ohnishi, and O. Berton Antidepressant actions of histone deacetylase inhibitors J Neurosci 29 2009 11451 11460
43. S.A. Craig Betaine in human nutrition Am J Clin Nutr 80 2004 539 549
44. A.B. Csoka, and M. Szyf Epigenetic side-effects of common pharmaceuticals: A potential new field in medicine and pharmacology Med Hypotheses 73 2009 770 780
45. C. Czech, G. Tremp, and L. Pradier Presenilins and Alzheimer's disease: Biological functions and pathogenic mechanisms Prog Neurobiol 60 2000 363 384
46. J.R. Davie, and V.A. Spencer Control of histone modifications J Cell Biochem Suppl 32-33 1999 141 148
47. J.J. Day, and J.D. Sweatt DNA methylation and memory formation Nat Neurosci 13 2010 1319 1323
48. R.M. de Oliveira, J. Sarkander, A.G. Kazantsev, and T.F. Outeiro SIRT2 as a therapeutic target for age-related disorders Front Pharmacol 3 2012 82
49. B. De Strooper, P. Saftig, K. Craessaerts, H. Vanderstichele, G. Guhde, and W. Annaert Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein Nature 391 1998 387 390
50. H. Ding, P.J. Dolan, and G.V. Johnson Histone deacetylase 6 interacts with the microtubule-associated protein tau J Neurochem 106 2008 2119 2130
51. F. Docagne, C. Gabriel, N. Lebeurrier, S. Lesne, Y. Hommet, and L. Plawinski Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription Biochem J 383 2004 393 399
52. G. Donmez, D. Wang, D.E. Cohen, and L. Guarente SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10 Cell 142 2010 320 332
53. R. Dosunmu, H. Alashwal, and N.H. Zawia Genome-wide expression and methylation profiling in the aged rodent brain due to early-life Pb exposure and its relevance to aging Mech Ageing Dev 133 2012 435 443
54. M.A. Faghihi, F. Modarresi, A.M. Khalil, D.E. Wood, B.G. Sahagan, and T.E. Morgan Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase Nat Med 14 2008 723 730
55. L.A. Farrer, L.A. Cupples, L. Connor, P.A. Wolf, and J.H. Growdon Association of decreased paternal age and late-onset Alzheimer's disease. An example of genetic imprinting? Arch Neurol 48 1991 599 604
56. D.M. Fass, S.A. Reis, B. Ghosh, K.M. Hennig, N.F. Joseph, and W.N. Zhao Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity Neuropharmacology 64 2013 81 96
57. A.P. Feinberg Epigenetics at the epicenter of modern medicine JAMA 299 2008 1345 1350
58. J. Feng, S. Fouse, and G. Fan Epigenetic regulation of neural gene expression and neuronal function Pediatr Res 61 2007 58R 63R
59. J. Feng, Y. Zhou, S.L. Campbell, T. Le, E. Li, and J.D. Sweatt Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons Nat Neurosci 13 2010 423 430
60. A. Fischer, F. Sananbenesi, X. Wang, M. Dobbin, and L.H. Tsai Recovery of learning and memory is associated with chromatin remodelling Nature 447 2007 178 182
61. A.S. Fleisher, D. Truran, J.T. Mai, J.B. Langbaum, P.S. Aisen, and J.L. Cummings Chronic divalproex sodium use and brain atrophy in Alzheimer disease Neurology 77 2011 1263 1271
62. A. Fuso, L. Seminara, R.A. Cavallaro, F. D'Anselmi, and S. Scarpa S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production Mol Cell Neurosci 28 2005 195 204
63. D.P. Gavin, and R.P. Sharma Histone modifications, DNA methylation, and schizophrenia Neurosci Biobehav Rev 34 2010 882 888
64. D. Globisch, M. Munzel, M. Muller, S. Michalakis, M. Wagner, and S. Koch Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates PLoS One 5 2010 e15367
65. A. Goate, M.C. Chartier-Harlin, M. Mullan, J. Brown, F. Crawford, and L. Fidani Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease Nature 349 1991 704 706
66. M. Gottlicher, S. Minucci, P. Zhu, O.H. Kramer, A. Schimpf, and S. Giavara Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J 20 2001 6969 6978
67. J. Graff, D. Rei, J.S. Guan, W.Y. Wang, J. Seo, and K.M. Hennig An epigenetic blockade of cognitive functions in the neurodegenerating brain Nature 483 2012 222 226
68. S.G. Gray, and T.J. Ekstrom The human histone deacetylase family Exp Cell Res 262 2001 75 83
69. K.N. Green, J.S. Steffan, H. Martinez-Coria, X. Sun, S.S. Schreiber, and L.M. Thompson Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau J Neurosci 28 2008 11500 11510
70. J.S. Guan, S.J. Haggarty, E. Giacometti, J.H. Dannenberg, N. Joseph, and J. Gao HDAC2 negatively regulates memory formation and synaptic plasticity Nature 459 2009 55 60
71. S. Gupta, S.Y. Kim, S. Artis, D.L. Molfese, A. Schumacher, and J.D. Sweatt Histone methylation regulates memory formation J Neurosci 30 2010 3589 3599
72. T. Hamaguchi, K. Ono, and M. Yamada REVIEW: curcumin and Alzheimer's disease CNS Neurosci Ther 16 2010 285 297
73. J. Hardy, and G.A. Higgins Alzheimer's disease: The amyloid cascade hypothesis Science 256 1992 184 185
74. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics Science 297 2002 353 356
75. S.S. Hebert, K. Horre, L. Nicolai, A.S. Papadopoulou, W. Mandemakers, and A.N. Silahtaroglu Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression Proc Natl Acad Sci U S A 105 2008 6415 6420
76. C. Heim, and E.B. Binder Current research trends in early life stress and depression: Review of human studies on sensitive periods, gene-environment interactions, and epigenetics Exp Neurol 233 2012 102 111
77. S. Henikoff, and M.A. Matzke Exploring and explaining epigenetic effects Trends Genet 13 1997 293 295
78. M. Hiramatsu, O. Takiguchi, A. Nishiyama, and H. Mori Cilostazol prevents amyloid beta peptide(25-35)-induced memory impairment and oxidative stress in mice Br J Pharmacol 161 2010 1899 1912
79. P.W. Hoffman, and J.M. Chernak DNA binding and regulatory effects of transcription factors SP1 and USF at the rat amyloid precursor protein gene promoter Nucleic Acids Res 23 1995 2229 2235
80. E. Hoffmann, J. Wald, S. Lavu, J. Roberts, C. Beaumont, and J. Haddad Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man Br J Clin Pharmacol 75 2013 186 196
81. M. Holler, G. Westin, J. Jiricny, and W. Schaffner Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated Genes Dev 2 1988 1127 1135
82. R. Holtzer, N. Scarmeas, D.J. Wegesin, M. Albert, J. Brandt, and B. Dubois Depressive symptoms in Alzheimer's disease: Natural course and temporal relation to function and cognitive status J Am Geriatr Soc 53 2005 2083 2089
83. I. Houston, C.J. Peter, A. Mitchell, J. Straubhaar, E. Rogaev, and S. Akbarian Epigenetics in the human brain Neuropsychopharmacology 38 2013 183 197
84. C.L. Hsieh In vivo activity of murine de novo methyltransferases, Dnmt3a and Dnmt3b Mol Cell Biol 19 1999 8211 8218
85. Y. Huang, and L. Mucke Alzheimer mechanisms and therapeutic strategies Cell 148 2012 1204 1222
86. K. Huber, and G. Superti-Furga After the grape rush: Sirtuins as epigenetic drug targets in neurodegenerative disorders Bioorg Med Chem 19 2011 3616 3624
87. M. Hutton, C.L. Lendon, P. Rizzu, M. Baker, S. Froelich, and H. Houlden Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 Nature 393 1998 702 705
88. B. Inkster, E.M. Strijbis, M. Vounou, L. Kappos, E.W. Radue, and P.M. Matthews Histone deacetylase gene variants predict brain volume changes in multiple sclerosis Neurobiol Aging 34 2013 238 247
89. K. Iqbal, F. Liu, C.X. Gong, C. Alonso Adel, and I. Grundke-Iqbal Mechanisms of tau-induced neurodegeneration Acta Neuropathol 118 2009 53 69
90. R. Jaenisch, and A. Bird Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals Nat Genet 33 2003 245 254 (Suppl.)
91. R.W. Johnstone Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer Nat Rev Drug Discov 1 2002 287 299
92. P.L. Jones, G.J. Veenstra, P.A. Wade, D. Vermaak, S.U. Kass, and N. Landsberger Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription Nat Genet 19 1998 187 191
93. C. Julien, C. Tremblay, V. Emond, M. Lebbadi, N. Salem Jr., and D.A. Bennett Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease J Neuropathol Exp Neurol 68 2009 48 58
94. T.C. Karagiannis, and K. Ververis Potential of chromatin modifying compounds for the treatment of Alzheimer's disease Pathobiol Aging Age Relat Dis 2 2012
95. N.S. Key Hyperhomocyst(e)inemia Curr Treat Options Cardiovasc Med 2 2000 65 72
96. M. Kilgore, C.A. Miller, D.M. Fass, K.M. Hennig, S.J. Haggarty, and J.D. Sweatt Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease Neuropsychopharmacology 35 2010 870 880
97. D. Kim, M.D. Nguyen, M.M. Dobbin, A. Fischer, F. Sananbenesi, and J.T. Rodgers SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis EMBO J 26 2007 3169 3179
98. M. Kim, L.A. Thompson, S.D. Wenger, and C.L. O'Bryant Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma Ann Pharmacother 46 2012 1340 1348
99. S. Kishikawa, T. Murata, H. Kimura, K. Shiota, and K.K. Yokoyama Regulation of transcription of the Dnmt1 gene by Sp1 and Sp3 zinc finger proteins Eur J Biochem 269 2002 2961 2970
100. R.J. Klose, and A.P. Bird Genomic DNA methylation: The mark and its mediators Trends Biochem Sci 31 2006 89 97
101. D. Knopman, and M. Patterson An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients Alzheimer Dis Assoc Disord 15 2001 162 165
102. E. Korzus Manipulating the brain with epigenetics Nat Neurosci 13 2010 405 406
103. E. Korzus, M.G. Rosenfeld, and M. Mayford CBP histone acetyltransferase activity is a critical component of memory consolidation Neuron 42 2004 961 972
104. T. Koseki, A. Mouri, T. Mamiya, Y. Aoyama, K. Toriumi, and S. Suzuki Exposure to enriched environments during adolescence prevents abnormal behaviours associated with histone deacetylation in phencyclidine-treated mice Int J Neuropsychopharmacol 15 2012 1489 1501
105. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
106. O.H. Kramer, P. Zhu, H.P. Ostendorff, M. Golebiewski, J. Tiefenbach, and M.A. Peters The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 EMBO J 22 2003 3411 3420
107. S. Kreth, N. Thon, and F.W. Kreth Epigenetics in human gliomas Cancer Lett 2013 (in press)
108. D.K. Lahiri, B. Maloney, and N.H. Zawia The LEARn model: An epigenetic explanation for idiopathic neurobiological diseases Mol Psychiatry 14 2009 992 1003
109. D.K. Lahiri, N.H. Zawia, N.H. Greig, K. Sambamurti, and B. Maloney Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model Biogerontology 9 2008 375 379
110. V.M. Lee, M. Goedert, and J.Q. Trojanowski Neurodegenerative tauopathies Annu Rev Neurosci 24 2001 1121 1159
111. J.M. Levenson, K.J. O'Riordan, K.D. Brown, M.A. Trinh, D.L. Molfese, and J.D. Sweatt Regulation of histone acetylation during memory formation in the hippocampus J Biol Chem 279 2004 40545 40559
112. J.M. Levenson, T.L. Roth, F.D. Lubin, C.A. Miller, I.C. Huang, and P. Desai Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus J Biol Chem 281 2006 15763 15773
113. Y. Levkovitz, J.E. Alpert, C.E. Brintz, D. Mischoulon, and G.I. Papakostas Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder J Affect Disord 136 2012 1174 1178
114. G.P. Lim, T. Chu, F. Yang, W. Beech, S.A. Frautschy, and G.M. Cole The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse J Neurosci 21 2001 8370 8377
115. L. Liu, Y. Li, and T.O. Tollefsbol Gene-environment interactions and epigenetic basis of human diseases Curr Issues Mol Biol 10 2008 25 36
116. L. Liu, T. van Groen, I. Kadish, and T.O. Tollefsbol DNA methylation impacts on learning and memory in aging Neurobiol Aging 30 2009 549 560
117. R. Loy, and P.N. Tariot Neuroprotective properties of valproate: potential benefit for AD and tauopathies J Mol Neurosci 19 2002 303 307
118. G.S. Mack To selectivity and beyond Nat Biotechnol 28 2010 1259 1266
119. B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, and R. Pazdur FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 2007 1247 1252
120. M.G. Marcu, Y.J. Jung, S. Lee, E.J. Chung, M.J. Lee, and J. Trepel Curcumin is an inhibitor of p300 histone acetylatransferase Med Chem 2 2006 169 174
121. N.P. Maric, and D.M. Svrakic Why schizophrenia genetics needs epigenetics: a review Psychiatr Danub 24 2012 2 18
122. K.C. Martin, and Y.E. Sun To learn better, keep the HAT on Neuron 42 2004 879 881
123. D. Mastroeni, A. Grover, E. Delvaux, C. Whiteside, P.D. Coleman, and J. Rogers Epigenetic changes in Alzheimer's disease: Decrements in DNA methylation Neurobiol Aging 31 2010 2025 2037
124. D. Mastroeni, A. Grover, E. Delvaux, C. Whiteside, P.D. Coleman, and J. Rogers Epigenetic mechanisms in Alzheimer's disease Neurobiol Aging 32 2011 1161 1180
125. D. Mastroeni, A. McKee, A. Grover, J. Rogers, and P.D. Coleman Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease PLoS One 4 2009 e6617
126. M.P. Mattson, B. Cheng, D. Davis, K. Bryant, I. Lieberburg, and R.E. Rydel beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity J Neurosci 12 1992 376 389
127. I. Maze, and E.J. Nestler The epigenetic landscape of addiction Ann N Y Acad Sci 1216 2011 99 113
128. K.R. Mifsud, M. Gutierrez-Mecinas, A.F. Trollope, A. Collins, E.A. Saunderson, and J.M. Reul Epigenetic mechanisms in stress and adaptation Brain Behav Immun 25 2011 1305 1315
129. J. Mill Toward an integrated genetic and epigenetic approach to Alzheimer's disease Neurobiol Aging 32 2011 1188 1191
130. C.A. Miller, S.L. Campbell, and J.D. Sweatt DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity Neurobiol Learn Mem 89 2008 599 603
131. C.A. Miller, and J.D. Sweatt Covalent modification of DNA regulates memory formation Neuron 53 2007 857 869
132. S.W. Min, S.H. Cho, Y. Zhou, S. Schroeder, V. Haroutunian, and W.W. Seeley Acetylation of tau inhibits its degradation and contributes to tauopathy Neuron 67 2010 953 966
133. M. Miwa, M. Tsuboi, Y. Noguchi, A. Enokishima, T. Nabeshima, and M. Hiramatsu Effects of betaine on lipopolysaccharide-induced memory impairment in mice and the involvement of GABA transporter 2 J Neuroinflammation 8 2011 153
134. D.L. Molfese Advancing neuroscience through epigenetics: Molecular mechanisms of learning and memory Dev Neuropsychol 36 2011 810 827
135. P. Moretti, and H.Y. Zoghbi MeCP2 dysfunction in Rett syndrome and related disorders Curr Opin Genet Dev 16 2006 276 281
136. L.D. Morrison, D.D. Smith, and S.J. Kish Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease J Neurochem 67 1996 1328 1331
137. C. Mulder, N.S. Schoonenboom, E.E. Jansen, N.M. Verhoeven, G.J. van Kamp, and C. Jakobs The transmethylation cycle in the brain of Alzheimer patients Neurosci Lett 386 2005 69 71
138. N.N. Nalivaeva, N.D. Belyaev, and A.J. Turner Sodium valproate: An old drug with new roles Trends Pharmacol Sci 30 2009 509 514
139. X. Nan, H.H. Ng, C.A. Johnson, C.D. Laherty, B.M. Turner, and R.N. Eisenman Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 393 1998 386 389
140. S. Naruse, G. Thinakaran, J.J. Luo, J.W. Kusiak, T. Tomita, and T. Iwatsubo Effects of PS1 deficiency on membrane protein trafficking in neurons Neuron 21 1998 1213 1221
141. A. Nebbioso, V. Carafa, R. Benedetti, and L. Altucci Trials with 'epigenetic' drugs: An update Mol Oncol 6 2012 657 682
142. M. New, H. Olzscha, and N.B. La Thangue HDAC inhibitor-based therapies: Can we interpret the code? Mol Oncol 6 2012 637 656
143. A. Nguyen, T.A. Rauch, G.P. Pfeifer, and V.W. Hu Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain FASEB J 24 2010 3036 3051
144. J. Nunez-Iglesias, C.C. Liu, T.E. Morgan, C.E. Finch, and X.J. Zhou Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation PLoS One 5 2010 e8898
145. Y. Oike, A. Hata, T. Mamiya, T. Kaname, Y. Noda, and M. Suzuki Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: Implications for a dominant-negative mechanism Hum Mol Genet 8 1999 387 396
146. M. Okano, D.W. Bell, D.A. Haber, and E. Li DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development Cell 99 1999 247 257
147. A.M. Oliveira, T.J. Hemstedt, and H. Bading Rescue of aging-associated decline in Dnmt3a2 expression restores cognitive abilities Nat Neurosci 15 2012 1111 1113
148. B.A. Orr, M.C. Haffner, W.G. Nelson, S. Yegnasubramanian, and C.G. Eberhart Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma PLoS One 7 2012 e41036
149. T.F. Outeiro, O. Marques, and A. Kazantsev Therapeutic role of sirtuins in neurodegenerative disease Biochim Biophys Acta 1782 2008 363 369
150. C.L. Peterson, and M.A. Laniel Histones and histone modifications Curr Biol 14 2004 R546 R551
151. F. Petrij, R.H. Giles, H.G. Dauwerse, J.J. Saris, R.C. Hennekam, and M. Masuno Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP Nature 376 1995 348 351
152. C.J. Phiel, F. Zhang, E.Y. Huang, M.G. Guenther, M.A. Lazar, and P.S. Klein Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J Biol Chem 276 2001 36734 36741
153. P. Pollwein, C.L. Masters, and K. Beyreuther The expression of the amyloid precursor protein (APP) is regulated by two GC-elements in the promoter Nucleic Acids Res 20 1992 63 68
154. P. Provost MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases Brain Res 1338 2010 58 66
155. I.A. Qureshi, and M.F. Mehler Epigenetic mechanisms underlying human epileptic disorders and the process of epileptogenesis Neurobiol Dis 39 2010 53 60
156. A. Raghavan, and Z.A. Shah Sirtuins in neurodegenerative diseases: A biological-chemical perspective Neurodegener Dis 9 2012 1 10
157. A. Ricobaraza, M. Cuadrado-Tejedor, A. Perez-Mediavilla, D. Frechilla, J. Del Rio, and A. Garcia-Osta Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model Neuropsychopharmacology 34 2009 1721 1732
158. J.M. Ringman, S.A. Frautschy, E. Teng, A.N. Begum, J. Bardens, and M. Beigi Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study Alzheimers Res Ther 4 2012 43
159. E.I. Rogaev, W.J. Lukiw, O. Lavrushina, E.A. Rogaeva, and P.H. St George-Hyslop The upstream promoter of the beta-amyloid precursor protein gene (APP) shows differential patterns of methylation in human brain Genomics 22 1994 340 347
160. S.A. Ropacki, and D.V. Jeste Epidemiology of and risk factors for psychosis of Alzheimer's disease: A review of 55 studies published from 1990 to 2003 Am J Psychiatry 162 2005 2022 2030
161. J.H. Rubinstein, and H. Taybi Broad thumbs and toes and facial abnormalities. A possible mental retardation syndrome Am J Dis Child 105 1963 588 608
162. S. Scarpa, A. Fuso, F. D'Anselmi, and R.A. Cavallaro Presenilin 1 gene silencing by S-adenosylmethionine: A treatment for Alzheimer disease? FEBS Lett 541 2003 145 148
163. N. Schonrock, and J. Gotz Decoding the non-coding RNAs in Alzheimer's disease Cell Mol Life Sci 69 2012 3543 3559
164. F.A. Schroeder, C.L. Lin, W.E. Crusio, and S. Akbarian Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse Biol Psychiatry 62 2007 55 64
165. D.J. Selkoe Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease Trends Neurosci 16 1993 403 409
166. D.J. Selkoe Preventing Alzheimer's disease Science 337 2012 1488 1492
167. B.R. Selvi, J.C. Cassel, T.K. Kundu, and A.L. Boutillier Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases Biochim Biophys Acta 1799 2010 840 853
168. A. Sengupta, J. Kabat, M. Novak, Q. Wu, I. Grundke-Iqbal, and K. Iqbal Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules Arch Biochem Biophys 357 1998 299 309
169. S. Seshadri, A. Beiser, J. Selhub, P.F. Jacques, I.H. Rosenberg, and R.B. D'Agostino Plasma homocysteine as a risk factor for dementia and Alzheimer's disease N Engl J Med 346 2002 476 483
170. M.D. Shahbazian, and H.Y. Zoghbi Rett syndrome and MeCP2: Linking epigenetics and neuronal function Am J Hum Genet 71 2002 1259 1272
171. R. Sherrington, E.I. Rogaev, Y. Liang, E.A. Rogaeva, G. Levesque, and M. Ikeda Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease Nature 375 1995 754 760
172. M. Shimojo, N. Sahara, M. Murayama, H. Ichinose, and A. Takashima Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1 Neurosci Res 57 2007 446 453
173. M. Shoji, T.E. Golde, J. Ghiso, T.T. Cheung, S. Estus, and L.M. Shaffer Production of the Alzheimer amyloid beta protein by normal proteolytic processing Science 258 1992 126 129
174. K.D. Siegmund, C.M. Connor, M. Campan, T.I. Long, D.J. Weisenberger, and D. Biniszkiewicz DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons PLoS One 2 2007 e895
175. A.J. Silva, J.H. Kogan, P.W. Frankland, and S. Kida CREB and memory Annu Rev Neurosci 21 1998 127 148
176. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
177. T.L. Spires-Jones, L.M. Fox, A. Rozkalne, R. Pitstick, G.A. Carlson, and A.G. Kazantsev Inhibition of sirtuin 2 with sulfobenzoic acid derivative AK1 is non-toxic and potentially neuroprotective in a mouse model of frontotemporal dementia Front Pharmacol 3 2012 42
178. W. Stunkel, and R.M. Campbell Sirtuin 1 (SIRT1): The misunderstood HDAC J Biomol Screen 16 2011 1153 1169
179. Y. Su, J. Ryder, B. Li, X. Wu, N. Fox, and P. Solenberg Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing Biochemistry 43 2004 6899 6908
180. G.M. Subaiea, L.I. Adwan, A.H. Ahmed, K.E. Stevens, and N.H. Zawia Short-term treatment with tolfenamic acid improves cognitive functions in AD mice Neurobiol Aging 2013 (in press)
181. F.A. Sultan, and J.J. Day Epigenetic mechanisms in memory and synaptic function Epigenomics 3 2011 157 181
182. Y.M. Sung, T. Lee, H. Yoon, A.M. Dibattista, J.M. Song, and Y. Sohn Mercaptoacetamide-based class II HDAC inhibitor lowers Abeta levels and improves learning and memory in a mouse model of Alzheimer's disease Exp Neurol 239 2013 192 201
183. K.E. Szulwach, X. Li, Y. Li, C.X. Song, H. Wu, and Q. Dai 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging Nat Neurosci 14 2011 1607 1616
184. R.E. Tanzi The genetics of Alzheimer disease Cold Spring Harb Perspect Med 2 2012
185. R.E. Tanzi, D.M. Kovacs, T.W. Kim, R.D. Moir, S.Y. Guenette, and W. Wasco The gene defects responsible for familial Alzheimer's disease Neurobiol Dis 3 1996 159 168
186. M.M. Taqi, I. Bazov, H. Watanabe, D. Sheedy, C. Harper, and K. Alkass Prodynorphin CpG-SNPs associated with alcohol dependence: Elevated methylation in the brain of human alcoholics Addict Biol 16 2011 499 509
187. P.N. Tariot, L.S. Schneider, J. Cummings, R.G. Thomas, R. Raman, and L.J. Jakimovich Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 68 2011 853 861
188. H. Tohgi, K. Utsugisawa, Y. Nagane, M. Yoshimura, Y. Genda, and M. Ukitsu Reduction with age in methylcytosine in the promoter region -224 approximately -101 of the amyloid precursor protein gene in autopsy human cortex Brain Res Mol Brain Res 70 1999 288 292
189. M. Townsend When will Alzheimer's disease be cured? A pharmaceutical perspective J Alzheimers Dis 24 Suppl. 2 2011 43 52
190. A.C. Tricco, S. Vandervaart, C. Soobiah, E. Lillie, L. Perrier, and M.H. Chen Efficacy of cognitive enhancers for Alzheimer's disease: Protocol for a systematic review and network meta-analysis Syst Rev 1 2012 31
191. S. Tucker, M. Ahl, A. Bush, D. Westaway, X. Huang, and J.T. Rogers Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5′ untranslated region Curr Alzheimer Res 2 2005 249 254
192. S. Tucker, M. Ahl, H.H. Cho, S. Bandyopadhyay, G.D. Cuny, and A.I. Bush RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine Curr Alzheimer Res 3 2006 221 227
193. C.G. Vecsey, J.D. Hawk, K.M. Lattal, J.M. Stein, S.A. Fabian, and M.A. Attner Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation J Neurosci 27 2007 6128 6140
194. E. Vilardo, C. Barbato, M. Ciotti, C. Cogoni, and F. Ruberti MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons J Biol Chem 285 2010 18344 18351
195. J. Wang, H. Fivecoat, L. Ho, Y. Pan, E. Ling, and G.M. Pasinetti The role of Sirt1: At the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology Biochim Biophys Acta 1804 2010 1690 1694
196. S.C. Wang, B. Oelze, and A. Schumacher Age-specific epigenetic drift in late-onset Alzheimer's disease PLoS One 3 2008 e2698
197. W.X. Wang, B.W. Rajeev, A.J. Stromberg, N. Ren, G. Tang, and Q. Huang The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1 J Neurosci 28 2008 1213 1223
198. T. Watanabe, N. Zhang, M. Liu, R. Tanaka, Y. Mizuno, and T. Urabe Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion Stroke 37 2006 1539 1545
199. E.J. Weeber, U. Beffert, C. Jones, J.M. Christian, E. Forster, and J.D. Sweatt Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning J Biol Chem 277 2002 39944 39952
200. M.D. Weingarten, A.H. Lockwood, S.Y. Hwo, and M.W. Kirschner A protein factor essential for microtubule assembly Proc Natl Acad Sci U S A 72 1975 1858 1862
201. R.L. West, J.M. Lee, and L.E. Maroun Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient J Mol Neurosci 6 1995 141 146
202. M.A. Wood, M.P. Kaplan, A. Park, E.J. Blanchard, A.M. Oliveira, and T.L. Lombardi Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage Learn Mem 12 2005 111 119
203. J. Wu, M.R. Basha, B. Brock, D.P. Cox, F. Cardozo-Pelaez, and C.A. McPherson Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): Evidence for a developmental origin and environmental link for AD J Neurosci 28 2008 3 9
204. J. Wu, M.R. Basha, and N.H. Zawia The environment, epigenetics and amyloidogenesis J Mol Neurosci 34 2008 1 7
205. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: Molecular mechanisms of action Oncogene 26 2007 5541 5552
206. F. Yang, G.P. Lim, A.N. Begum, O.J. Ubeda, M.R. Simmons, and S.S. Ambegaokar Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J Biol Chem 280 2005 5892 5901
207. R.W. Yen, P.M. Vertino, B.D. Nelkin, J.J. Yu, W. el-Deiry, and A. Cumaraswamy Isolation and characterization of the cDNA encoding human DNA methyltransferase Nucleic Acids Res 20 1992 2287 2291
208. N.H. Zawia, and M.R. Basha Environmental risk factors and the developmental basis for Alzheimer's disease Rev Neurosci 16 2005 325 337
209. N.H. Zawia, D.K. Lahiri, and F. Cardozo-Pelaez Epigenetics, oxidative stress, and Alzheimer disease Free Radic Biol Med 46 2009 1241 1249
210. A. Zovoilis, H.Y. Agbemenyah, R.C. Agis-Balboa, R.M. Stilling, D. Edbauer, and P. Rao microRNA-34c is a novel target to treat dementias EMBO J 30 2011 4299 4308